{"id": "chatcmpl-8JXEBS6QGPxSFATGXZqNk9vCmwpCv", "object": "chat.completion", "created": 1699666651, "model": "gpt-4-0613", "choices": [{"index": 0, "message": {"role": "assistant", "content": "1. The statement is discussing the examination of pooled per-protocol ocular end points.\n2. This examination is based on two conjunctival allergen challenge (CAC) clinical trials.\n3. The trials are related to the dual-action antihistamine bepotastine besilate ophthalmic solution (BBOS) 1.5%.\n4. Bepotastine besilate ophthalmic solution (BBOS) is a dual-action antihistamine.\n5. The concentration of BBOS used in the trials is 1.5%.\n6. The trials involve a conjunctival allergen challenge."}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 79, "completion_tokens": 129, "total_tokens": 208}, "temperature": 0, "max_tokens": 512, "top_p": 1, "frequency_penalty": 0, "presence_penalty": 0, "messages": [{"role": "system", "content": "Statement: To examine the pooled per-protocol ocular end points from two conjunctival allergen challenge (CAC) clinical trials of the dual-action antihistamine bepotastine besilate ophthalmic solution (BBOS) 1.5%.\n\nList all the facts we explicitly know from the statement. Make each fact as atomic as possible."}]}